Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EDI048 in Healthy Volunteers
NCT05275855Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KDU 731 in cryptosporidiosis (2 arms), sponsored by Novartis. Primary endpoint: Number of participants with Adverse Events (AEs) up to 9 weeks. Started Apr 2022; status: completed.
02
Drugs
KDU 731
03
Conditions
cryptosporidiosis
Beyond the preview
Go deeper on NCT05275855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275855.